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Non-small cell lung cancer (NSCLC) is the most
frequent cause of cancer deaths worldwide; nearly
half contain mutations in the receptor tyrosine
kinase/RAS pathway. Here we show that RAS-
pathway mutant NSCLC cells depend on the tran-
scription factor GATA2. Loss of GATA2 reduced the
viability of NSCLC cells with RAS-pathway muta-
tions, whereas wild-type cells were unaffected. Inte-
grated gene expression and genome occupancy
analyses revealed GATA2 regulation of the protea-
some, and IL-1-signaling, and Rho-signaling path-
ways. These pathways were functionally significant,
as reactivation rescued viability after GATA2 deple-
tion. In a Kras-driven NSCLC mouse model, Gata2
loss dramatically reduced tumor development.
Furthermore, Gata2 deletion in established Kras
mutant tumors induced striking regression. Although
GATA2 itself is likely undruggable, combined
suppression of GATA2-regulated pathways with clin-
ically approved inhibitors caused marked tumor
clearance. Discovery of the nononcogene addiction
of KRAS mutant lung cancers to GATA2 presents
a network of druggable pathways for therapeutic
exploitation.INTRODUCTION
Lung cancer is the most prevalent cancer type worldwide by
both diagnosis and mortality, with non-small cell lung cancer642 Cell 149, 642–655, April 27, 2012 ª2012 Elsevier Inc.(NSCLC) featuring as the most common histological subtype
(Ferlay et al., 2010). Among NSCLC patients, the most
frequently mutated oncogenes are the RAS family of GTPases
and various receptor tyrosine kinases (RTKs), constituting
nearly half of all NSCLCs. Though mutations in the RAS family
in human cancers have been known for 30 years, therapeutic
targeting of RAS has so far proven intractable. Moreover,
although tyrosine kinase inhibitors exhibit striking efficacy in
NSCLC patients with mutant RTKs, patients inevitably develop
therapeutic resistance. Thus, novel therapies are needed to
target RAS-pathway mutant NSCLCs.
One potentially promising approach has been to target path-
ways acting downstream of RAS: combined inhibition of ERK
and PI 3-kinase pathways with small-molecule inhibitors can
impair the growth of Krasmutant mouse lung tumors (Engelman
et al., 2008).Moving beyond direct RAS effectors, several groups
have screened for factors and pathways necessary for KRAS
mutant cancer cell survival. An initial candidate was the TANK-
binding kinase 1 (TBK1), found in a short hairpin RNA (shRNA)
screen of the kinome (Barbie et al., 2009). In RAS mutant cells,
RalB activates TBK1, whichmaintains survival through activation
of the NF-kB pathway, a signaling cascade found to be neces-
sary in a mouse model of mutant Kras-driven NSCLC (Chien
et al., 2006; Meylan et al., 2009).
Beyond antiapoptotic factors, several groups have found
targets that promote KRAS mutant cancers via maintenance of
cellular proliferation. One of the initial mutant KRAS synthetic
lethal shRNA screens found mitotic regulators to be specifically
necessary for mutant cell fitness (Luo et al., 2009). Conversely,
Barbacid and colleagues found that both human cancer cells
and a mutant Kras mouse model depend on the G1/S regulator
Cdk4 (Puyol et al., 2010). Moreover, functional analysis of an
oncogenic KRAS expression signature revealed the Wilms’
tumor gene WT1 to be required in mutant KRAS cells via
regulation of cellular senescence (Vicent et al., 2010). In sum,
these studies suggest a broad role for cell-cycle control in onco-
genic KRAS-mediated tumorigenesis.
Although these investigations suggest various candidates for
RAS-pathway mutant dependency in NSCLC, several important
issues require deeper investigation. First, it is unclear whether
these factors are required only in KRAS mutant cancer cells or
more broadly in cancers that activate the RAS-signaling path-
ways, like activated RTKs or inactivated RAS GTPase-activating
proteins (GAPs). Second, these candidates have generally
focused on single processes upon which KRAS mutant cancer
cells might depend. Single targeting of candidates and path-
ways will likely only transiently suppress tumorigenesis due to
the development of resistance. Consequently, combination
treatments that inhibit multiple dependencies might prove
a more efficacious therapeutic route. Third, although these
targets were shown to be required in mutant cancer cells, the
effect of whole-body loss of these targets in the context of the
tumor has in many cases not been described. Because any
potential therapeutic agent will likely operate throughout the
patient, it is important to determine what toxicities might be pre-
sented by target inhibition in the organismal milieu. In addition,
the previous in vivo studies described have generally focused
on tumor development—the effect on forming the tumor in the
absence of the target—and not on the more clinically relevant
issue of tumor maintenance—the effect of disabling the target
in a preformed tumor. Finally, most of the previously described
screens, though generating candidate factors for drug develop-
ment, have not provided novel therapeutic strategies derived
from clinically licensed inhibitors. Considering the significant
time required for drug development and testing, it would be
intriguing to envisage therapeutic regimens with compounds
already in clinical use.
Here we describe the transcription factor GATA2 as required
for the survival of RAS-pathway mutant NSCLC. Both in vitro
and in vivo, loss of GATA2 reduces mutant NSCLC cell line
viability. Combined gene expression and chromatin occupancy
analysis reveals a broad network of pathways controlled by
GATA2 in RAS-pathway mutant NSCLC cells. These pathways
are salient to GATA2-mediated survival, as their reactivation
restores viability in response to GATA2 depletion. Furthermore,
Gata2 is required forKrasmutant tumorigenesis in an autochtho-
nous mouse model, and whole-organism loss of Gata2 induces
regression of established Kras mutant lung tumors without
drastic toxicities. Finally, combined inhibition of GATA2-regu-
lated pathways with clinically available inhibitors recapitulates
the effect of GATA2 loss, causing a robust suppression of estab-
lished Kras mutant NSCLC and providing an immediately appli-
cable therapeutic strategy for RAS-pathway mutant NSCLC.
RESULTS
KRAS Mutant NSCLC Cells Specifically Require GATA2
for Survival
To discover novel genes necessary inKRASmutant cancer cells,
we performed an RNA interference (RNAi) screen targeting some
7,000 human genes in a panel of KRAS mutant and wild-type
(WT) cancer cells. Among other factors (including KRAS itself),we found that loss of the transcription factor GATA2 led to
a decrease in KRAS mutant cell viability and an increase in
apoptosis (M.S., M.M.-A., D.C.H., and J.D., unpublished data).
To extend these findings, we analyzed 26 NSCLC cell lines, of
which 14 were KRAS mutant and 12 were WT. Short-term
GATA2 knockdown led to specific decreased cell viability and
increased apoptosis in KRAS mutant NSCLC cells, comparable
to the effect seen with loss of KRAS itself (Figure 1A and Fig-
ure S1A available online). Comparison of expression across the
panel revealed no significant differences in GATA2 expression
between mutant and WT cells (data not shown). Interestingly,
the relative effect of GATA2 loss on viability correlated with the
extent of GATA2 knockdown in mutant but not WT cells (Fig-
ure S1B). Moreover, there was a modest relationship between
the effect of GATA2 knockdown and that of KRAS knockdown
in mutant but not WT cells (p < 0.05 for KRAS mutant cells by
Pearson’s correlation). Also, comparison of the effect of
GATA2 depletion in the panel with other frequent mutations in
NSCLC (such as TP53, STK11, andCDKN2A) revealed no signif-
icant delineations, emphasizing the specific role for mutant
KRAS in GATA2 dependency (Figure S1C). Taken together,
these findings suggest that KRAS mutant NSCLC cells depend
upon GATA2 for survival.
GATA2 Is Necessary for the Viability of RAS-Pathway
Mutant NSCLC Cells
Although the above findings demonstrate that GATA2 was
required in NSCLC cells with mutations in known RAS-pathway
components, it was unclear whether this dependency occurred
in NSCLCs containing other mutant oncogenes, such as RTKs
like epidermal growth factor receptor (EGFR). To address this,
we used small-interfering RNAs (siRNAs) against both KRAS
and GATA2 in the NSCLC cell lines A549 (KRAS mutant), PC9
(EGFR mutant), and H322M (WT). As expected, A549 cells ex-
hibited reduced viability with loss of either KRAS or GATA2,
whereas H322M cells were unaffected (Figure 1B). Surprisingly,
PC9 cells were also dependent on GATA2 for viability. Examina-
tion of additional EGFRmutant (H3255) andKRASmutant (H441)
NSCLC cells revealed similar effects for GATA2 (Figure S1D).
Importantly, both KRAS and GATA2 were knocked down effec-
tively with the siRNAs (Figure S1E). In sum, these findings
suggest that GATA2 is broadly required in the survival of RAS-
pathway mutant NSCLC.
To further validate GATA2, we designed shRNAs against
GATA2. To this end, one shRNA (shGATA2.1) achieved substan-
tial knockdown of GATA2 in A549 and PC9 cells relative to
a control (shGAPDH) and a nonfunctional GATA2 shRNA
(shGATA2.2) (Figure 1C). Notably, shGATA2.1-expressing A549
and PC9 cells had greatly reduced viability relative to the other
shRNAs but did not affect WT H322M cells (Figure 1D). Here-
after, shGATA2.1 is referred to as ‘‘shG’’ and shGAPDH as
‘‘shC.’’
Examination of additional KRAS and EGFR mutant cells
showed a striking dependency on GATA2 for mutant cell viability
(Figure S1F). Moreover, this dependency was broadly observed
in oncogene-driven NSCLC cells, as cell lines with mutations in
NRAS, NF1, and EML4-ALK all exhibited reduced viability in
response to GATA2 knockdown. In contrast, WT NSCLC cellsCell 149, 642–655, April 27, 2012 ª2012 Elsevier Inc. 643
Figure 1. GATA2 Is Required in RAS-
Pathway Mutant NSCLC
(A) Fourteen KRAS mutant and twelve KRAS WT
NSCLC lines were transfected with control siRNA,
siRNA targeting GATA2, or siRNA targeting KRAS.
Cell titer blue and APO-one assays were used
to measure viability and apoptosis, respectively.
*p < 0.05.
(B) KRASmutant (A549), EGFR mutant (PC9), and
WT (H322M) NSCLC cells were transfected with
control siRNA (RISC-free), KRAS siRNA, or GATA2
siRNA. Cell numbers were counted 72 hr later.
(C) shRNAs targeting GAPDH (shGAPDH) and
GATA2 (shGATA2.1 and shGATA2.2) were in-
fected into A549 and PC9 cells, followed by
western blotting for GATA2 and tubulin.
(D) ShRNA-infected A549, PC9, and H322M cells
were plated, and cell numbers were counted as
above.
(E) Western blotting was performed on shRNA-
infected A549 and PC9 cells for cleaved PARP.
See also Figure S1.were unaffected by GATA2 depletion (Figure S1G). Importantly,
RAS-pathway mutant andWT lung cancer cells express compa-
rable amounts of GATA2 and exhibit similar levels of knockdown
with the shRNA (Figure S1H). To resolve off-target effects of the
shRNA, we rescued GATA2 expression with a GATA2 cDNA in
which the shRNA-binding site had been mutated to prevent
knockdown (Figure S1I). Notably, the shRNA-mutated cDNA
achieves a near-complete rescue of viability, demonstrating
the specificity of the effect on GATA2 loss (Figure S1J). More-
over, to determine whether this dependency was conserved
from human to mouse lung cancer cells, we generated shRNAs
targeting murine Gata2. These shRNAs achieved substantial
knockdown of GATA2 and caused a striking decrease in the
growth of a murine Kras mutant NSCLC cell line (Figures S1K
and S1L).
These results indicate that GATA2 loss reduces RAS-pathway
mutant cell viability but do not indicate whether this effect is due
to increased apoptosis or impaired proliferation. Thus, we exam-
ined both apoptotic markers and the cell-cycle distribution in
GATA2 knockdown cells. With GATA2 depletion in mutant lung
cancer cells, we observed elevated PARP cleavage, a marker644 Cell 149, 642–655, April 27, 2012 ª2012 Elsevier Inc.of apoptotic cell death (Figure 1E).
Conversely, we observed no significant
change in the cell-cycle profiles of mutant
cancer cells with GATA2 knockdown
(Figure S1M). Taken together, these
results show that GATA2 is necessary
for the survival of RAS-pathway mutant
NSCLC.
GATA2 Is Necessary for Oncogene-
Driven Lung Cancer Growth In Vivo
Although the above studies revealed that
GATA2 is required for RAS-pathway
mutant NSCLC viability in vitro, it was
unclear whether this was maintainedin vivo. Thus, we examined the ability of GATA2-depleted lung
cancer cells to alter tumor xenograft growth. As seen in Fig-
ure 2A, injection of control shRNA-expressing RAS-pathway
mutant NSCLC cells led to robust tumor growth. In contrast,
GATA2 knockdown cells completely abrogated tumor formation,
with no detectable lesions forming over 9 months. The effect of
GATA2 on RAS-pathway mutant tumors was specific, as loss
of GATA2 had no impact on tumor growth in WT NSCLC cells
(Figure 2B). Collectively, these results indicate that GATA2 is
crucial for tumorigenesis in RAS-pathway mutant lung cancer.
GATA2 Regulates the Proteasome via Control of Nrf1
To elucidate the mechanisms by which GATA2 maintains RAS-
pathway mutant NSCLC survival, we performed gene expres-
sion analysis on A549 and PC9 cells expressing either control
or GATA2 shRNA. As GATA2 was likely to operate via broad
regulatory nodes, gene set enrichment analysis (GSEA) was
performed (a list of enriched gene sets is included in Fig-
ure S2A). One of the most striking candidate pathways nega-
tively enriched in GATA2 knockdown cells was the proteasome
pathway (Figure S2B). This was intriguing, as several screens
Figure 2. GATA2 Is Necessary for Oncogene-Driven Lung Tumorigenesis In Vivo
(A) A549 and PC9 cells infected with GAPDH (shC) and GATA2 (shG) shRNAs were injected subcutaneously into nude mice. Tumor volumes were measured with
calipers. Values are mean ± SEM (n = 8).
(B) H520 and H322M cells infected with shRNAs were injected into nude mice as above. Values are mean ± SEM (n = 8).for KRAS synthetic lethal factors revealed dependencies on
components of the proteasome (Barbie et al., 2009; Luo
et al., 2009). Because numerous proteasome components ap-
peared downregulated with GATA2 loss, we suspected that
transcriptional control of the proteasome was disrupted.
Recent reports have described the transcription factor Nrf1 as
a regulator of the proteasome (Radhakrishnan et al., 2010).
Quantitative RT-PCR (qRT-PCR) revealed downregulation of
Nrf1 and proteasome components with GATA2 knockdown
independent of genotype (Figure 3A). Moreover, this transcrip-
tional control was germane to proteasome function, as GATA2
loss impaired proteasome activity in mutant and WT NSCLC
cells (Figure 3B).
To determine the role of the proteasome in GATA2-mediated
survival, we expressed either Nrf1 or a dominant-negative form
of the proteasome inhibitor USP14 (USP1414) in RAS-pathway
mutant cells (Lee et al., 2010). As seen in Figure 3C, expression
of either dominant-negative USP14 or Nrf1 was functionally
salient, as each re-established proteasome function after
GATA2 depletion, with more robust rescue occurring in the
USP14SF cells. Nrf1 was important for proteasome transcript
levels, as it partially restored expression of several components
(Figure S2C). After GATA2 loss, we observed a modest but
discernible rescue of viability with both USP14SF and Nrf1 (Fig-ure 3D); the variation in rescue is likely due to the incomplete
restoration in proteasome expression by Nrf1, whereas USP14SF
can posttranslationally elicit more complete rescue of protea-
some function. Taken together, these findings suggest that pro-
teasome function is sufficient for partial rescue of viability in
response to GATA2 loss in RAS-pathway mutant NSCLC.
To examine further the dependency of RAS-pathway mutant
lung cancer cells on the proteasome, we depleted proteasome
components and inhibited the proteasome with bortezomib in
our panel of KRAS mutant/WT NSCLC cells. We observed no
significant differential viability with either proteasome compo-
nent loss or bortezomib treatment (Figures S2D and S2E),
although there is a slight tendency formutant cells to be affected.
Importantly, both approaches inhibited proteasome function
comparably to GATA2 loss (Figure S2F). Taken together, these
results indicate that proteasome inhibition is insufficient to differ-
entially affect KRAS mutant NSCLC viability. Because of the
failure of proteasome loss to differentially affect mutant cell
viability, we wanted to ensure that the effects of GATA2 on the
proteasome were on-target. To do so, we examined whether
the shRNA-resistant GATA2 cDNA restored proteasome func-
tion. With the rescue system, we observed a complete reversal
or proteasome inhibition, demonstrating that the effects of
GATA2 on the proteasome are on-target (Figure S2G). We alsoCell 149, 642–655, April 27, 2012 ª2012 Elsevier Inc. 645
Figure 3. GATA2 Regulates Transcription of the Proteasome via Nrf1
(A) qRT-PCR was performed for a control transcript (PLK1), Nrf1, PSMA3, PSMA4, and PSMB8 in shRNA-infected A549, PC9, H322M, and H520 cells.
Expression of target genes in shRNA cells was normalized to PLK1 levels. Target gene expression in shC cells was set to 1 to determine relative expression in shG
cells. Values are mean ± SEM with propagated error (n = 3).
(B) Western blotting was performed on shRNA-infected A549, PC9, H322M, and H520 cells for ubiquitin (conjugated and free), STAT5, ERK, and RAS.
(C) Western blotting was performed on shRNA-infected A549 cells expressing empty vectors, dominant-negative USP14 (USP14SF), or Nrf1 for ubiquitin
(conjugated and free), p110beta, Akt, and S6.
(D) shRNA-infected A549 and PC9 cells expressing empty vectors, USP14SF, or Nrf1 were plated and counted as in Figure 1D.
See also Figures S2 and S6.assessed whether the effects on the proteasome were caused
by elevated cell death by abrogating apoptosis with the caspase
inhibitor z-VAD-fmk (z-VAD). Whereas z-VAD completely
blocked the apoptosis induced by GATA2 loss, impaired protea-
some function was maintained (Figures S2H and S2I). Collec-
tively, these results suggest that the effects of GATA2 on the pro-
teasome are not merely a consequence of apoptosis driven by
GATA2 loss.646 Cell 149, 642–655, April 27, 2012 ª2012 Elsevier Inc.GATA2 Controls NF-kB Signaling through Regulation
of the IL-1 Pathway
Beyond the proteasome, we noted a striking transcriptional
repression of the IL-1- and NF-kB-signaling pathways with
GATA2 depletion (Figure S3A). The differential expression was
coupled to GATA2 genome occupancy, as chromatin immuno-
precipitation coupled to next-generation sequencing (ChIP-
seq) of GATA2 (to be discussed below) revealed enrichment of
IL-1 pathway genes like TRAF6 (Figure S3B). Validation of
GATA2 occupancy by ChIP-PCR revealed that GATA2 bound
TRAF6 only in RAS-pathway mutant cells, though it bound
PDK1 and ZFPM2 across all lung cancer cells (Figure 4A). More-
over, only RAS-pathway mutant cells exhibited loss of TRAF6
expression after GATA2 knockdown (Figure 4B). Collectively,
these findings indicate that GATA2 regulates expression of the
IL-1 pathway in RAS-pathway mutant NSCLC.
We then assessed the consequence of this on the NF-kB
pathway, an important downstream effector of IL-1 signaling
(O’Neill, 2008). As seen in Figure 4C, we observed a remarkable
suppression of an NF-kBpathway reporter inmutant lung cancer
cells, with little change in WT cells. The reduction of NF-kB
signaling was not downstream of GATA2-mediated apoptosis,
as GATA2 knockdown similarly suppressed NF-kB activity
when cell death was inhibited with z-VAD (Figure S3C). In sum,
these results suggest that GATA2 is necessary for activation of
the NF-kB cascade.
To determine a functional role for the IL-1 pathway in GATA2-
mediated viability, we expressed TRAF6 in RAS-pathwaymutant
lung cancer cells, as TRAF6 overexpression exogenously acti-
vates IL-1 signaling (Cao et al., 1996). TRAF6 expression largely
restored NF-kB signaling in response to GATA2 depletion (Fig-
ure 4D). Consequently, TRAF6 substantially rescued cell viability
after GATA2 loss (Figure 4E). These effects were not due to
TRAF6 regulation of GATA2 expression, as neither TRAF6 rescue
nor TRAF6 depletion by siRNA altered GATA2 protein levels
(Figures S3D and S3E). Overall, these findings demonstrate
that GATA2 regulation of IL-1 signaling is functionally germane
for RAS-pathway mutant cell survival.
Considering the substantial effect that the IL-1 pathway has
on both NF-kB signaling and RAS-pathwaymutant cell survival,
we then evaluated the immediate role of NF-kB on GATA2-
mediated viability. Expression of the NF-kB subunit RelA
caused a striking rescue of NF-kB activity in response to
GATA2 knockdown (Figure S3). Surprisingly, this only margin-
ally affected viability after GATA2 depletion (Figure S3G). More-
over, we tested whether loss of either IL-1 or NF-kB signaling
was sufficient to reduce mutant cell viability by depletion of
TRAF6 or NEMO, an essential activator of canonical NF-kB
signaling (Yamaoka et al., 1998). Though knockdown of either
factor was able to suppress NF-kB signaling (Figure S3H),
both caused only a modest reduction in viability (Figure 4F).
Furthermore, inhibition of IL-1 signaling by the antagonist
IL-1ra, although able to inhibit NF-kB activity (Figure S3I), had
little effect on RAS-pathway mutant cell viability (Figure S3J).
Collectively, these results demonstrate that whereas TRAF6
substantially rescues GATA2-mediated survival (to be dis-
cussed below), inhibition of either IL-1 or NF-kB signaling is
insufficient to phenocopy GATA2 loss.
GATA2Directly Regulates Rho Target Genes toMaintain
Pathway Activity
To better understand how GATA2 maintains mutant NSCLC
viability, we carried out ChIP-seq for GATA2 in mutant (A549
and PC9) and WT (H322M and H520) lung cancer cells. As
corroboration of our ChIP-seq results, we assayed a set of peaks
from the sequencing results across the four cell lines by ChIP-PCR and found occupancy with GATA2 (Figure S4A). Moreover,
ChIP-PCR with a second, independent GATA2 antibody compa-
rably enriched for several target genes from the ChIP-seq (Fig-
ure S4B), demonstrating the specificity of these targets for
GATA2. Taken together, these findings validate the results of
our ChIP-seq in a panel of lung cancer cell lines.
We then determined whether there was enrichment of gene
sets particularly in mutant cells. Strikingly, we observed
numerous Rho-related signaling pathways as being broadly
occupied by GATA2 in mutant cells but not in WT cells (Fig-
ure S4C). Among these Rho-pathway genes is the Rho kinase
ROCK1, as seen in Figure 5A. By ChIP-PCR, we verified that
several of the Rho-pathway genes were bound by GATA2 in
mutant but not WT NSCLC cells (Figure 5B). Furthermore, our
original GSEA included Rho-related cell adhesion pathways
among the GATA2-regulated gene sets (Figure S4D), and qRT-
PCR revealed reduced expression of Rho-pathway targets with
GATA2 depletion (Figure 5C). In total, these results suggest
that GATA2 directly regulates expression of Rho-signaling
components.
Recognizing this regulation of Rho targets by GATA2, we as-
sessed the functional consequences of GATA2 loss on Rho
activity. GATA2 knockdown triggered a striking decline in GTP-
bound Rho (including RhoA, RhoB, and RhoC isoforms) in
mutant lung cancer cells (Figure 5D). This was intriguing, as
one of the GATA2-regulated Rho target genes was EPHA3, an
ephrin receptor and upstream activator of Rho signaling (Pitu-
lescu and Adams, 2010). Notably, depletion of EPHA3 caused
a reduction in GTP-bound Rho that was similar to the loss of
GATA2, both at the steady state and in response to stimulation
with Ephrin A5 (Figures S4E and S4F).
This effect on Rho-pathway activation was specific to RAS-
pathway mutant lung cancer cells, as phosphorylation of the
myosin light chain (pMLC), a substrate of ROCK1 and down-
streammarker for Rho signaling, was suppressed in mutant cells
with GATA2 knockdown but was unaffected in WT cells (Fig-
ure 5E). To address the possibility that the effect on Rho
signaling was due to apoptosis caused by GATA2 loss, we
examined pMLC in GATA2-depleted cells in the presence of
z-VAD. Importantly, pMLC was comparably suppressed in the
presence of z-VAD (Figure S4G). Taken together, these effects
demonstrate that GATA2 is necessary for Rho-pathway activa-
tion in RAS-pathway mutant NSCLC.
We explored the functional role for Rho in GATA2-mediated
viability by pathway rescue. Constitutively active RhoAG14V fully
restored Rho-GTP levels and pathway activity (Figure 5F). When
we examined viability, activated Rho substantially rescued
mutant cell survival in response to GATA2 depletion (Figure 5G).
Interestingly, this rescue was reversed by the ROCK inhibitor
fasudil, which efficiently abrogated pMLC (Figures S5A and
S5B). In line with this, restoration of ROCK function via the
ROCK:ER fusion also substantially restored viability in response
to GATA2 depletion (Croft et al., 2004) (Figures S5C and S5D).
We then examined whether the Rho pathway was individually
necessary for RAS-pathway mutant cell survival. Depletion of
ROCK1 had only marginal effects on mutant cell viability, in spite
of robust suppression of pMLC (Figures S5E and S5F). More-
over, knockdown of a panel of Rho-pathway components orCell 149, 642–655, April 27, 2012 ª2012 Elsevier Inc. 647
Figure 4. GATA2 Controls IL-1/NF-kB Signaling via TRAF6
(A) ChIP was performed with a control antibody (IgG) or an antibody for GATA2 in A549, PC9, H322M, and H520 cells, and PCRwas performed for TRAF6, PDK1,
and ZFPM2.
(B) qRT-PCR was performed for TRAF6 in A549, PC9, H322M, and H520 cells as in Figure 3A. Values are mean ± SEM (n = 3).
(C) NF-kB and control reporter plasmids were cotransfected into shRNA-infected A549, PC9, H322M, and H520 cells. Twenty-four hours later, luciferase assays
were performed. Pathway activity was determined by normalizing luciferase from the NF-kB reporter to the control.
(D) NF-kB and control reporter plasmids were cotransfected into shRNA-infected A549 and PC9 cells expressing empty vector or TRAF6. Luciferase assays were
performed as above.
(E) ShRNA-infected A549 and PC9 cells expressing empty vector or TRAF6 were plated and counted as in Figure 1D.
(F) A549 and PC9 cells were transfected with control siRNA or siRNAs targeting GATA2, TRAF6, or NEMO as in Figure 1B. Cell numbers were counted 72 hr later.
See also Figures S3, S4, and S6.
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treatment with the ROCK inhibitor fasudil exhibited no differential
viability in our panel of 26 NSCLC cell lines (Figures S5G and
S5H). In sum, these results suggest that although Rho pathway
activation is sufficient to rescue viability in response to GATA2
loss, it is not solely necessary for mutant NSCLC survival.
GATA2 Regulates Rho Target Genes via a STAT5
Transcriptional Complex
To understand how GATA2 differentially occupied Rho targets,
we examined the DNA sequence motifs enriched in the mutant
versus WT GATA2 ChIPs. Strikingly, we observed the STAT5
response element as specifically enriched in mutant cells (Hen-
nighausen and Robinson, 2008) (Figure 5H). Thus, we predicted
that GATA2 and STAT5 interact at Rho-pathway target genes.
We first examined this putative GATA2/STAT5 interaction by
coimmunoprecipitations of the factors and found that the factors
did immunoprecipitate with one another in mutant but not WT
cells (Figure 5I). Furthermore, as seen in Figure 5J, by ChIP/
re-ChIP analyses, we found that GATA2 and STAT5 interact at
Rho target gene loci particularly in mutant lung cancer cells.
Importantly, whereas Rho target genes did not ChIP in
a GATA2/STAT5 complex in WT cells, GATA2 targets common
to mutant and WT lung cancer cells were enriched in all cells,
demonstrating the capacity to isolate GATA2 targets in WT cells.
Collectively, these results demonstrate that GATA2 is bound to
Rho target genes via a complex with STAT5.
Considering the dependency on GATA2-regulated pathways
in RAS-pathway mutant cancer cells, it was unclear whether
GATA2 was regulated by activated oncogenes. To address
this, we inhibited oncogenic EGFR in PC9 cells with the tyrosine
kinase inhibitor erlotinib. Interestingly, although erlotinib treat-
ment efficiently suppressed MAP kinase signaling, it did not
affect STAT5 phosphorylation (Figure S5I). Consequently, erloti-
nib treatment had no effect on GATA2 occupancy of either IL-1
or Rho target genes (Figure S5J). To further explore the interac-
tion of GATA2- and RAS-pathway signaling, we examined the
effect of depleting KRAS on the GATA2 network. Notably,
whereas KRAS knockdown did suppress phosphorylation of
ERK and Akt, it did not affect proteasome activity, Rho signaling,
or NF-kB activity (Figures S5K and S5L). Taken together, these
results suggest that GATA2 operates orthogonally to RAS-
pathway signaling.
To elucidate the differential occupancy of GATA2 in RAS-
pathway mutant cells, we examined a panel of KRAS mutant,
EGFR mutant, and WT NSCLC cell lines. This analysis revealed
a trend toward higher levels of STAT5 phosphorylation in mutant
versusWT cells (Figure S5M). Interestingly, expression of consti-
tutively active STAT5 in WT cells was sufficient to drive GATA2
occupancy at Rho target genes (Figure S5N). We then examined
whether STAT5 was individually required in RAS-pathway
mutant NSCLC. Notably, we found that depletion of a single
STAT5 isoform, STAT5B, was sufficient to both deplete total
STAT5 and substantially suppress Rho signaling (Figure S5O).
In addition, STAT5B knockdown caused a reduction in Rho
target gene expression that was similar to the loss of GATA2 (Fig-
ure S5P). Yet knockdown of STAT5B caused only a modest
decline in viability (Figure S5Q). In total, these findings indicate
that STAT5, although necessary for Rho-pathway function,does not engender the same dependency as GATA2 itself in
RAS-pathway mutant NSCLC.
The GATA2 Transcriptional Network Is General and
Displays Considerable Crosstalk
Though the above results describe a dependency on GATA2-
regulated pathways in two mutant lung cancers, we wanted to
assess the extent of the GATA2 network in RAS-pathway mutant
NSCLC. To do so, we examined GATA2-regulated pathways in
three additional KRAS mutant and three additional WT lung
cancer cells after GATA2 loss. Similar to the effects seen earlier,
GATA2 depletion abrogated proteasome function across both
genotypes (Figure S6A). Moreover, GATA2 loss inhibited Rho
signaling and suppressed NF-kB activity only in KRAS mutant
cells, as seen above (Figures S6A and S6B). In sum, these results
show that GATA2-regulated pathways are broadly maintained in
RAS-pathway mutant NSCLC.
Because of the striking dependency of mutant NSCLC on the
GATA2 network, we examined whether there were interactions
across GATA2-regulated pathways. Notably, we found control
of NF-kB signaling by both the proteasome and Rho signaling,
as activation of either was capable of restoring NF-kB activity
with GATA2 loss (Figures S6C and S6D). These findings corrob-
orate studies demonstrating an interaction of the proteasome
and Rho pathways with NF-kB (Perona et al., 1997; Xue et al.,
2011). Moreover, Rho signaling in response to GATA2 knock-
down was rescued by activation of the IL-1 pathway with
TRAF6 (Figure S6E). This is in line with earlier observations of
various cytokines, including IL-1, stimulating Rho signaling
(Sanz-Moreno et al., 2011). This Rho signal induction is the likely
cause of the substantial rescue observedwith TRAF6 expression
after GATA2 depletion that is not recapitulated with activation of
NF-kB alone. In contrast, activation of IL-1 or Rho signaling had
no effect on proteasome function after GATA2 loss (Figure S6F).
Collectively, these results outline amultifactorial GATA2 network
in RAS-pathway mutant NSCLC (Figure 5K).
Gata2 Is Required for Oncogenic Kras-Driven Lung
Tumorigenesis
To determine the relevance of this network in vivo, we condition-
ally deleted Gata2 in an autochthonous model of Kras mutant
NSCLC (Charles et al., 2006; Jackson et al., 2001). To do so,
we generated KrasLSL-G12D; Gata2+/+,Flox/+,Flox/Flox mice (here-
after referred to as KG +/+, F/+, and F/F mice, respectively)
and infected their lungs with adenovirus that expresses Cre re-
combinase (Ad-Cre). Eight weeks after infection, we compared
the cohort histopathologically and observed a very large reduc-
tion in tumor burden in KG F/F animals compared to both KG +/+
and F/+ controls (Figures 6A and 6B).Moreover, both KG F/+ and
KG F/F mice exhibited a significant decrease in tumor number
relative to KG +/+ controls, with KG F/F animals exhibiting
a more striking decline (Figure 6C). In contrast, the average sizes
of the tumors that did arise were comparable among KG +/+,
F/+, and F/F mice (Figure 6D). To characterize the tumors in
KG F/F mice, we prepared DNA from these lesions and analyzed
recombination. Intriguingly, tumors from KG F/F mice retained
an unrecombined floxed Gata2 allele, whereas the Kras allele
was completely recombined in the same lesions (Figure 6E).Cell 149, 642–655, April 27, 2012 ª2012 Elsevier Inc. 649
Figure 5. GATA2 Regulates Rho Pathway Signaling via a Transcriptional Complex with STAT5
(A) Representative GATA2 ChIP-seq images from the IGV Genome Browser for ROCK1 in A549 and PC9 cells.
(B) ChIP was performed in A549, PC9, H322M, and H520 cells as in Figure 4A, and PCR was performed for ROCK1, EPHA3, and CDC42.
(C) qRT-PCR was performed for ROCK1, EPHA3, and CDC42 as in Figure 3A. Values are mean ± SEM (n = 3).
(D) Rho-GTP pull-down assays were performed in shRNA-infected A549 and PC9 cells. Western blotting was performed on pull-downs (Rho-GTP) and total cell
lysates (total Rho).
(E) Western blotting was performed on shRNA-infected A549, PC9, H322M, and H520 cells for pMLC and total MLC.
(F) Rho-GTP pull-down assays were performed in shRNA-infected A549 and PC9 cells expressing empty vector or RhoAG14V (RhoA). Western blotting was
performed on pull-downs (Rho-GTP) and total cell lysates (total Rho, pMLC, and MLC).
(G) shRNA-infected A549 and PC9 cells expressing empty vector or RhoAG14V (RhoA) were plated and counted as in Figure 1D.
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Taken together, these results indicate that Gata2 is requisite for
oncogenic Kras-driven lung tumor initiation.
Loss of Gata2-Induced Regression in Established Kras
Mutant Tumors
Although the above findings suggest a role for Gata2 in Kras
mutant NSCLC, they do not demonstrate thatGata2 is necessary
for themaintenance of establishedKrasmutant lung tumors, only
for their development. We thus generated KrasLA2-G12D/+;
Rosa26CreERT2/+; Gata2+/+,Flox/+,Flox/Flox (hereafter referred to as
LG +/+, F/+, and F/F mice, respectively). In these animals, lung
tumors develop spontaneously from expression of mutant Kras
due to spontaneous recombination (Johnson et al., 2001). We
then induce whole-body deletion of Gata2 using the CreERT2
conditional allele expressed from the Rosa26 locus (Hameyer
et al., 2007). After 3 days of tamoxifen treatment, we observed
recombination of theGata2 locus in both organs and lung tumors
of LG F/+ and F/F mice, along with Kras recombination in the
lung tumors (Figure 6F). Western blot analysis revealed complete
loss of GATA2 protein after 3 days of tamoxifen treatment in LG
F/F lung tumors (Figure 6G). We also observed inhibition of the
proteasome and Rho-signaling pathways in LG F/F lesions,
along with elevation of the apoptotic marker cleaved caspase
3. In total, these findings show that tamoxifen treatment leads
to efficient, whole-body Gata2 locus recombination, with subse-
quent loss of GATA2 protein and inhibition of regulated pathways
in lung tumors.
We then assessed the effect ofGata2 loss on established lung
lesions.We scanned animals bymicro-CT the day before tamox-
ifen treatment and then treated animals for 1 week with tamox-
ifen. We then monitored animals by micro-CT for 1 month. As
seen in Figures 6H and 6I, we found thatGata2 loss had a striking
effect, with near-complete abrogation of lung tumors in treated
LG F/F mice. Longitudinal analysis of LG +/+ animals revealed
a substantial increase in tumor size over time; a more modest
increase in LG F/+ mice; and extensive regression in LG F/F
mice (Figure 6J). Importantly, systemicGata2 loss waswell toler-
ated as tamoxifen treatment of Rosa26CreERT2/+; Gata2+/+,F/+,F/F
mice revealed only a transient drop in body weight independent
of Gata2 genotype (Figure S7A). Although these results could be
due partially to lost GATA2 function in the endothelial lineage
(Kanki et al., 2011; Linnemann et al., 2011), these findings in
Kras mutant NSCLC models demonstrate that Gata2 not only
affects tumor initiation but also triggers major regression in es-
tablished lesions.
Combined Inhibition of the Proteasome and Rho
Signaling Robustly Suppresses KrasMutant Tumor
Growth
Though cellular and genetic studies reveal a dependency on
GATA2 for RAS-pathway mutant NSCLC, the known difficulty(H) Meme analysis of A549 and PC9 GATA2 ChIP peaks reveals enrichment of th
(I) IPs were performed in A549, PC9, H322M, andH520 cells, and western blotting
(J) ChIP/re-ChIP was performed in A549, PC9, H520, and H322M cells, and PCR
(K) Model of GATA2 function in oncogene-driven NSCLC. GATA2 regulates a tra
signaling pathways, which maintain RAS-pathway mutant survival through NF-k
See also Figures S4, S5, and S6.of targeting transcription factors with small molecules raises
issues as to how to translate this into the clinical setting.
However, our studies revealed a GATA2-regulated signaling
network, several components of which can be inhibited with clin-
ically available compounds. In particular, the proteasome, and
indirectly NF-kB, can be inhibited with the FDA-licensed drug
bortezomib and the Rho/ROCK-signaling cascade with fasudil,
which has been approved for clinical use in Japan. To examine
combined inhibition of these pathways on KRASmutant NSCLC,
we first treated a subset of KRAS mutant and WT cells with the
individual drugs and their combination. Notably, whereas there
was a substantial effect of combined bortezomib/fasudil treat-
ment in mutant cells, the effect was much less pronounced in
WT cells (Figure S7B). To exclude any potential off-target effects
of these drugs, we also combined siRNAs targeting ROCK1 and
various proteasome components in RAS-pathway mutant cells.
Relative to control siRNAs or single pathway inhibition, mutual
knockdown of ROCK1 and the proteasome combined to reduce
mutant cell viability (Figure S7C). Collectively, these results
provide a rationale for combining proteasome and Rho-pathway
inhibition in Kras mutant NSCLC.
To extend these results in vivo, we treatedKrasLA2-G12Dmice at
12 weeks old, an age at which these animals have an extensive
lung tumor burden (Johnson et al., 2001), with either drug
individually or both in combination. We found that bortezomib
and fasudil treatments for 3 days clearly suppress proteasome
and ROCK signaling, respectively (Figure 7A). However, only
combined treatment with bortezomib and fasudil elicited
increased caspase 3 cleavage, demonstrating elevated
apoptosis in those lesions. We then established a 4 week treat-
ment protocol with bortezomib and fasudil individually or in
combination. Notably, after 4 weeks of treatment, we still
observed substantial repression of the proteasome and ROCK
signaling in the lung (Figure S7D). Subsequent histopathological
analysis of these animals revealed a modest decrease in tumori-
genesis with bortezomib or fasudil treatment alone and a very
substantial decrease in tumor growth with the combination (Fig-
ure 7B). Quantitation of these effects revealed major reductions
in tumor burden, tumor number, and average tumor size with
the combination therapy relative to both control and single-drug
treatments (Figures 7C–7E). Although the effect of this combina-
tion on the stroma might also contribute to inhibition of tumor
growth, as seen for ROCK/JAK inhibition in squamous cell
cancers (Sanz-Moreno et al., 2011), our combined genetic and
pharmacological analyses suggest a strong cell-autonomous
effect of GATA2 pathway suppression on the tumor tissue, as
in the KrasLSL-G12D model Gata2 is deleted only in tumor cells
and not stroma, endothelial, or other host tissues. Collectively,
these results demonstrate that joint treatment with clinically
available inhibitors causes substantial regression of Kras-mutant
NSCLC.e STAT5 response element.
for GATA2 and STAT5 was performed on 5% total cell lysate (input) and the IPs.
was performed for ROCK1, EPHA3, CDC42, PDK1, and ZFPM2.
nscriptional network composed of the proteasome, IL-1-signaling, and Rho-
B-dependent and NF-kB-independent mechanisms.
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Figure 6. Gata2 Is Required for Kras-Driven Autochthonous Lung Tumorigenesis
(A) Representative histological images of lungs from KG +/+, F/+, and F/F mice 8 weeks after infection with adenovirus that expresses Cre (Ad-Cre). Black arrows
indicate lung adenomas. Magnification is 13.
(B) Tumor burden (tumor area as a percentage of total lung area) in KG +/+ (n = 15), F/+ (n = 9), and F/F (n = 13) mice 8 weeks after Ad-Cre. ***p < 0.0005.
(C) Tumor number in the above mice 8 weeks after Ad-Cre. *p < 0.05; ***p < 0.0005.
(D) Tumor size in the above mice 8 weeks after Ad-Cre.
(E) Gata2 and Kras recombination was assessed in KG F/F lung tumors. Gata2F/F (F/F control) and Gata2/ (/ control) tissues served as controls for Gata2.
KrasLSL-G12D (LSL/+ control) and KrasG12D (K/+ control) mouse embryonic fibroblasts (MEFs) served as controls for Kras.
(F)Gata2 and Kras recombination was assessed in LG F/+ and F/F animals. Mice were fed a tamoxifen diet for 3 days. Animals were culled, and spleen, liver, and
lung tumor DNA was analyzed. Gata2F/+ (F/+ control), Gata2+/ (+/ control), Gata2F/F (F/F control), and Gata2/ (/ control) tissues served as controls for
Gata2. KrasLA2-G12D (LA2/+ control) tissue and LKR13 (K/+ control) cells served as controls for Kras.
(G) GATA2 loss and pathway modulation were assessed in LG +/+, F/+, and F/F animals. Mice were fed a tamoxifen diet for 3 days. Animals were culled, and lung
tumor lysates analyzed. Western blotting was performed for caspase 3 (full-length [FL] and cleaved), ubiquitin (conjugated and free), STAT5, GATA2, p38, pMLC,
and MLC.
(H) Representative LG +/+ and F/F lungs after tamoxifen diet. Animals were fed a tamoxifen diet for a week, monitored for 28 days, and then sacrificed. Black
arrows indicate lung tumors.
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Figure 7. Combined Inhibition of the Pro-
teasome and Rho Signaling Recapitulates
the Effect of GATA2 Loss on Oncogenic
Kras-Driven Tumorigenesis
(A) Twelve-week-old KrasLA2-G12D animals were
treated with PBS, bortezomib (BTZ), fasudil (Faz),
or bortezomib and fasudil (BTZ+Faz). After 3 days,
animals were culled, and western blotting was
performed on lung tumors for caspase 3 (full-
length [FL] and cleaved), ubiquitin (conjugated
and free), p110alpha, p38, pMLC, and MLC.
* represents a nonspecific band detected with
p110alpha.
(B) Representative histological images of lungs
from KrasLA2-G12D mice treated with PBS, BTZ,
Faz, or BTZ+Faz for 4 weeks, starting at 12 weeks
of age. Magnification is 13.
(C) Tumor burden in mice treated with PBS (n =
11), BTZ (n = 10), Faz (n = 10), or BTZ+Faz (n = 10)
for 4 weeks, starting at 12 weeks of age. *p < 0.05;
**p < 0.005; ***p < 0.0005.
(D) Tumor number in mice from (C). **p < 0.005;
***p < 0.0005.
(E) Tumor size in mice from (C). *p < 0.05; **p <
0.005; ***p < 0.0005.
See also Figure S7.DISCUSSION
The GATA2 Transcriptional Network Regulates RAS-
Pathway Mutant NSCLC Survival
In this report, we have shown that lung cancers with mutations in
KRAS and other oncogenes on the RTK/RAS pathway depend
upon GATA2 for survival. Through integrated analyses of gene
expression and genome occupancy, we found that this depen-
dency occurs via concurrent regulation of three pathways: the
proteasome machinery; the IL-1/NF-kB signaling pathway; and
the Rho-signaling cascade (Figure 5K). These pathways exhibit
extensive crosstalk, suggesting the network to be mutually rein-
forcing (Figures S6C–S6E). Interestingly, the proteasome has
been shown in several earlier screens to be a specific KRAS
dependency (Barbie et al., 2009; Luo et al., 2009). Our results
are in linewith this, thoughwe found that neither loss of individual(I) Representative transaxial images of LG +/+ and F/F lungs before and after tamoxifen diet. Animals w
a tamoxifen diet for a week. After 2 weeks, animals were scanned onceweekly for 3 weeks until sacrifice (day 3
0 and 35.
(J) Longitudinal quantification of LG lung tumors over time as described above. Tumor volumes from day 0 a
Red, black, and blue lines correspond to LG +/+ (n = 3 animals), F/+ (n = 2 animals), and F/F (n = 3 animals
See also Figure S7.
Cell 149, 642–6proteasome components nor protea-
some inhibition differentially reduces
KRAS mutant cell viability (Figures S2D
and S2E). Furthermore, the NF-kB
pathway has been previously described
as required in KRAS-driven lung cancer
in vitro and in vivo (Barbie et al., 2009;
Meylan et al., 2009). We have seen
a similar coordination of NF-kB- andRAS-pathway mutant cell survival, though we find that NF-kB
inhibition is neither necessary nor sufficient for mutant NSCLC-
specific killing (Figures 4F and S3F–SJ).
An intriguing discovery was the control of Rho signaling by
GATA2 in complex with STAT5. Earlier work from Marshall and
colleagues described interdependence between RAS and Rho
signaling in oncogenic transformation (Olson et al., 1998). More-
over, an earlier KRAS synthetic lethal screen found the ephrin
receptor EPHA6 to be specifically required in KRAS mutant
lung cancer cells (Barbie et al., 2009), and recent resequencing
has described mutations of multiple ephrin receptors in lung
adenocarcinoma (Ding et al., 2008). As the Rho pathway is a
major effector of ephrin signaling (Pitulescu and Adams, 2010),
these changes provide a basis for Rho dependency in NSCLC.
Our findings expand the role of GATA2-regulated pathways
to include RAS-pathway oncogene-mutated lung cancers.ere initially scanned by micro-CT (day 0) and fed
5).White arrows indicate detectable lesions at days
re set to 1, and relative tumor sizes were recorded.
) tumors, respectively.
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Intuitively, general dependencies in the RAS/RTK pathway
should occur, as these factors share a common signaling axis.
Moreover, resequencing of various cancers with mutations in
the RAS/RTK cascade have found mutations in these compo-
nents to be mutually exclusive, suggesting that they engender
a common effect (Ding et al., 2008). Surprisingly, we found that
GATA2 operates orthogonally to oncogenes, as suppression of
oncogenic signaling did not affect GATA2 genome occupancy
or regulated pathway function (Figures S5I–S5L). GATA2 has
no known oncogenic function in its own right and is not
controlled by signals emanating from the RTK/RAS pathway.
Thus, dependency on the GATA2 transcriptional network might
evolve as a stress-response mechanism in parallel to oncogene
signaling during tumorigenesis, and that selection for the
network in RAS-pathway mutant cells eventually converts into
dependency on continued GATA2 function, a form of nononco-
gene addiction.
Elucidation of the GATA2 Transcriptional Network
Exposes a Multiplicity of Druggable Intervention Points
Our investigations revealed a marked attenuation of autochtho-
nous Kras mutant NSCLC growth in response to systemic
Gata2 loss; similar effects were observed with whole-body inhi-
bition of the Myc-Max interaction in a related Kras mutant lung
tumor model (Soucek et al., 2008). However, these findings
face the issue of translation into clinically relevant therapies, as
DNA-binding proteins are traditionally considered undruggable
by the pharmaceutical industry (Darnell, 2002).
Through integrated analyses of gene expression and genome
occupancy, we defined a GATA2 network of signaling pathways
that present discrete avenues of therapeutic targeting. Conse-
quently, we combined inhibition of the proteasome and Rho/
ROCK signaling with the clinical compounds bortezomib and fa-
sudil, respectively. Considering the dramatic effects observed
with this regimen, we believe such a strategy may benefit
patients with RAS-pathway mutant NSCLC.
Beyond this initial approach, such treatment strategies could
be improved further by inhibition of IL-1 signaling with IL-1
receptor monoclonal antibodies (Dinarello, 2010). Moreover, as
this approach targets a network, one could envisage a multi-
tiered strategy to inhibit various points within the signaling path-
ways. For example, along with fasudil one could inhibit Rho
signaling upstreamat the ephrin receptorwith dasatinib (Montero
et al., 2011). Finally, asGATA2 functionswith STAT5 (Hennighau-
sen and Robinson, 2008), a transcription factor regulated by
phosphorylation, it would be intriguing to determine its regulatory
kinase or kinases, as these factors might serve as therapeutic
targets. We anticipate that this report will extend the basis for
combinatorial design of targeted therapies in lung cancer.
EXPERIMENTAL PROCEDURES
Detailed procedures are described in the Extended Experimental Procedures.
ChIP-Seq
ChIP assays were performed as described (Valouev et al., 2008). Both ChIP
samples and total chromatin were submitted for Illumina sequencing as
described (Schmidt et al., 2009). Details of computational analyses are in the
Extended Experimental Procedures.654 Cell 149, 642–655, April 27, 2012 ª2012 Elsevier Inc.Mouse Strains
KrasLSL-G12D and KrasLA2-G12D mice were from the Mouse Models of Human
Cancer Consortium (Johnson et al., 2001; Tuveson et al., 2004).Rosa26CreERT2
mice were from A. Berns (Hameyer et al., 2007). Gata2F mice were from the
Mutant Mouse Regional Resource Center (Charles et al., 2006). BALB/C
nude mice were from Charles River Laboratories. Animal husbandry details
are in the Extended Experimental Procedures.
Tamoxifen Treatment
Mice were given a tamoxifen diet as described (Blasco et al., 2011). Further
details are in the Extended Experimental Procedures.
Micro-CT Analysis
Micro-CT analysis was performed with the SkyScan 1176. LG mice were
scanned, given a tamoxifen diet for 1 week, and scanned weekly. Details are
in the Extended Experimental Procedures.
Drug Treatment In Vivo
Mice were treated with PBS, bortezomib, fasudil, or bortezomib and fasudil.
For 3 day treatments, tumor protein was collected. For 4 week treatments,
lungs were examined histologically or lung protein was collected. Details are
in the Extended Experimental Procedures.
Statistical Analysis
Values represent mean ± standard error of the mean (SEM). For the NSCLC
cell panel, significance was assessed with the Mann-Whitney test. For corre-
lation analyses, significance was assessed with the Pearson’s coefficient. For
the cell cycle, significance was analyzed via chi-square testing. For qRT-PCR,
error was propagated using standard methods. For histopathology, signifi-
cance was determined using the Student’s t test. For GSEA, significance
was determined using an empirical phenotype-based permutation test as
described (Subramanian et al., 2005). For GeneGo pathway enrichment,
statistical significance was assessed with t statistics.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Discussion, Extended Experi-
mental Procedures, seven figures, and one table and can be found with this
article online at doi:10.1016/j.cell.2012.02.059.
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